Nanobiotix Reports Initial Data From Pancreatic Cancer Trial
Biotechnology firm Nanobiotix has presented preliminary data from its Phase 1 study evaluating NBTXR3, a nano-drug activated by radiotherapy, for patients with locally advanced pancreatic cancer.
Paris and Cambridge, Mass.-based Nanobiotix has released initial clinical data from a Phase 1 study investigating NBTXR3, a radioenhancer composed of hafnium oxide nanoparticles, for the treatment of locally advanced pancreatic cancer.
The data were presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research (AACR). The study involved 15 patients who received NBTXR3 via endoscopic ultrasound-guided intratumoral injection followed by radiotherapy. The treatment was found to be feasible with a tolerable safety profile.
Among the 13 evaluable patients for efficacy, 12 (92.3%) achieved local disease control in the injected tumor. The median overall survival in the evaluable population was 21 months from diagnosis. These findings suggest that the combination of NBTXR3 and radiotherapy may offer promising local tumor control and support further development for pancreatic cancer.
NBTXR3 is designed to enhance the tumor-killing effect of radiotherapy. Its proof-of-concept was established in soft tissue sarcomas, for which it received a CE mark in Europe. Nanobiotix believes its physical mechanism of action allows for potential use across various solid tumors.